# Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses

> **NCT05765955** · PHASE1 · COMPLETED · sponsor: **Poolbeg Pharma plc** · enrollment: 36 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** POLB 001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05765955
- **Lead sponsor:** Poolbeg Pharma plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-22
- **Primary completion:** 2022-12-14
- **Final completion:** 2022-12-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05765955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05765955, "Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05765955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*